The Zenome platform supports the possibility to manage your genomic data while maintaining privacy and ability to make a profit from selling access to different parts of the genome. Zenome establishes equal conditions for drug development and for the progress of scientific and medical technologies. The principal Zenome customers of genetic information are companies interested in genetic targeting such as Google, Facebook, Unilever and pharmaceutical companies. On the Zenome platform, the user is engaged in many types of different interactions throughout the system. These interactions take place at different system levels, don’t interfere with each other, and involve different patterns of interactions. The participants who provide resources for the operation of this network receive payments for it in Zenome tokens.
Currently there is a problem of inequality in the genome industry. It means that the main part of personal genomic data is concentrated in data centers of genomic corporations, government, scientific and medical institutions, and pharmaceutical companies. Moreover, there is an issue of legal limitation of access to personal genomic data, as well as the absence of possibility for genomic data management and sharing. This genomic data monopolization dramatically inhibits the development in a number of scientific and medical fields.
Zenome offers the possibility of:
For more information about $ZNA tokenomics, download pdf here.